US pharma tariffs will have small revenue footprint but signal broader trade agenda
Tariffs on pharmaceutical imports announced by the US government last week contain broad exemptions that will likely prevent them from raising major revenues, but they send a broader signal about the...To view the full article, register now.
Already a subscriber? Click here to view full article